What is CoMind?
CoMind Technologies Limited is at the forefront of neurotechnology, developing innovative, non-invasive bedside measurement technology designed to provide healthcare professionals with access to critical neurophysiological signals. Their mission is to enhance patient outcomes across the healthcare continuum by improving clinical practices through advanced photonics technology. The company addresses a substantial unmet need in the neurotechnology sector, aiming to revolutionize how brain functions are monitored and treated.
How much funding has CoMind raised?
CoMind has raised a total of $59M across 1 funding round:
Other Financing Round
$59M
Other Financing Round (2025): $59M with participation from LocalGlobe, Plural VC, Octopus Ventures, Latitude, and Angelini Ventures
Key Investors in CoMind
LocalGlobe
LocalGlobe is an investor participating in the funding round.
Plural VC
Plural VC is a venture community focused on early-stage companies in the finance sector, providing both investment and intellectual capital.
Octopus Ventures
Octopus Ventures is a founder-focused venture capital firm backing companies across software, climate, health, consumer, and financial technology with long-term capital and guidance.
What's next for CoMind?
The recent major strategic investment signals a pivotal growth phase for CoMind, likely enabling the company to scale its operations, accelerate product development, and expand its market reach. This enterprise-level funding suggests a strong market validation and positions CoMind to further its mission of improving patient care through advanced neurotechnology. Future developments may focus on clinical trials, regulatory approvals, and broader commercialization efforts, solidifying its role in transforming neuro-diagnostics and treatment.
See full CoMind company page
